---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000195"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:34:32.268418+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track

## Summary
- Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.
- Cash and equivalents $427.6M as of Sep 30, 2024; net cash used in operations $59.2M.
- Roche-Genentech optioned first neuroscience phenomap for $30M; total potential $500M across multiple maps.
- Proposed Exscientia merger: shareholder vote Nov 12; scheme of arrangement expected Nov 20, 2024.
- Clinical milestones: Phase 2 CCM data encouraging; IND cleared for REC-1245; first patient dosed in Phase 2 C. diff.

## SEC filing metadata
- accession: 0001601830-24-000195
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000195/0001601830-24-000195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000195/rxrx-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000195
- JSON: https://secwatch.observer/filing/0001601830-24-000195.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.